Filtrer par catégorie
- Tous
- Congress
- Blog
- Congrès
- Ressource Scientifique
- Webinaire
- Poster
- Publication scientifique
- Communiqué de Presse
- Couverture presse
- Actualités
Filtrer par catégorie
Communiqué de Presse
26/09/2022
Servier exercises the exclusive worldwide license option of their collaboration program LRRK2
Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate
Communiqué de Presse
22/09/2022
OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement
Poster
02/09/2022
Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines
We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.
Publication scientifique
30/08/2022
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor Antagonist 177Lu-Satoreotide Tetraxetan and the Agonist 177Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
Read now our new scientific publication focused on Anti-Tumour Activity!
Communiqué de Presse
01/07/2022
ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.
Poster
29/06/2022
In vitro pharmacological profile of Compound A
Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.
Poster
29/06/2022
In vivo PK/PD profile of Compound A
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.
Actualités
11/04/2022
Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!
Poster
08/04/2022
Lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation
Get to know more about lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation!
Poster
08/04/2022
Mouse models of hepatocellular carcinoma
Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).
Poster
08/04/2022
Using individual or a consortium of bacteria for immuno-oncology research
Get to know more about the beneficial role of bacteria for cancer therapy. Oncodesign Services, vector Of Innovation in oncology, inflammation & Covid-19.
Webinaire
05/04/2022
[EN] How to Better Optimize an Oncology Drug Discovery Program
Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...